Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) CEO Robert Bitterman acquired 25,000 shares of the company’s stock in a transaction dated Monday, November 9th. The shares were purchased at an average cost of $0.82 per share, with a total value of $20,500.00. Following the acquisition, the chief executive officer owned 789,871 shares of the company’s stock, valued at approximately $647,694.22. This represents a 3.27% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Phio Pharmaceuticals Price Performance
Shares of PHIO stock traded up $0.01 during trading hours on Tuesday, reaching $0.85. 37,487 shares of the company were exchanged, compared to its average volume of 1,315,510. Phio Pharmaceuticals Corp. has a fifty-two week low of $0.75 and a fifty-two week high of $1.88. The stock’s fifty day moving average is $0.96 and its two-hundred day moving average is $1.08. The company has a market cap of $9.87 million, a price-to-earnings ratio of -0.68 and a beta of 0.93.
Phio Pharmaceuticals (NASDAQ:PHIO – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.36). On average, research analysts anticipate that Phio Pharmaceuticals Corp. will post -1.45 earnings per share for the current year.
Analyst Upgrades and Downgrades
Check Out Our Latest Report on PHIO
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.
Featured Articles
- Five stocks we like better than Phio Pharmaceuticals
- Microsoft’s Neocloud Pullback Isn’t a Crack in AI Demand
- Fox’s $22 Billion Roku Acquisition Reshapes Its Streaming Business
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
